Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Anjie Zhu"'
Autor:
Hanfang Jiang, Jianxin Zhong, Jing Wang, Guohong Song, Lijun Di, Bin Shao, Ruyan Zhang, Yaxin Liu, Anjie Zhu, Nan Wang, Huiping Li
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Background Cyclin‐dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy (ET) become standard‐of‐care for patients with hormone receptor‐positive, human epidermal growth factor receptor‐2 negative (HR+/HER2−) metastatic brea
Externí odkaz:
https://doaj.org/article/2ce3716600334395a7d32beb2fb0348e
Autor:
Ruyan Zhang, Yifei Chen, Xiaoran Liu, Xinyu Gui, Anjie Zhu, Hanfang Jiang, Bin Shao, Xu Liang, Ying Yan, Jiayang Zhang, Guohong Song, Huiping Li
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectivesThis study evaluated the efficacy and safety of apatinib (an oral small-molecule tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in patients with pretreated metastatic breast cancer in a real-world setting.Pat
Externí odkaz:
https://doaj.org/article/90bbfa76e4234f49859e0a0e94aff489
Autor:
Anjie Zhu, Peng Yuan, Nanlin Hu, Mingzhou Li, Wenmiao Wang, Xue Wang, Jian Yue, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li, Binghe Xu, Shanbo Cao, Giuseppe Lippi, Yoichi Naito, Mohammed A. Osman, Gustavo N. Marta, Gianluca Franceschini, Armando Orlandi
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 875-887 (2021)
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC.
Externí odkaz:
https://doaj.org/article/ff84631bd7354ef6954779789c081040
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
IntroductionWe performed this clinical trial to evaluate the efficacy and safety of apatinib and oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer (MBC).MethodsPatients with HER2-negative MBC previously treate
Externí odkaz:
https://doaj.org/article/fdf3294387634e5db007a5c957bf22a1
Autor:
Xue Wang, Anjie Zhu, Jiayu Wang, Fei Ma, Jing Liu, Ying Fan, Yang Luo, Pin Zhang, Qing Li, Binghe Xu, Peng Yuan
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Aromatase inhibitors (AIs) influence blood lipid profiles. However, relatively few studies have directly compared the treatment effects of steroidal and nonsteroidal AIs. Methods: A prospective single-center cohort study was conducted to
Externí odkaz:
https://doaj.org/article/1890d7aad98d472b93ba41aafbc54df4
Autor:
Anjie ZHU, Nan WANG, Zehui YUN, Xiaoran LIU, Xu LIANG, Ying YAN, Bin SHAO, Hanfang JIANG, Lijun DI, Guohong SONG, Huiping LI
Publikováno v:
Neoplasma; 2024, Vol. 71 Issue 4, p392-401, 112p
Publikováno v:
ACM Transactions on Multimedia Computing, Communications, and Applications. 19:1-21
Knowledge graphs often suffer from incompleteness, and knowledge graph completion (KGC) aims at inferring the missing triplets through knowledge graph embedding from known factual triplets. However, most existing knowledge graph embedding methods onl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb5732b5aa1f1d60b0c2e8e0ceb9fcbc
https://doi.org/10.1145/3545573
https://doi.org/10.1145/3545573
Publikováno v:
IEEE Transactions on Cybernetics. :1-12
Approximating the uncertainty of an emotional AI agent is crucial for improving the reliability of such agents and facilitating human-in-the-loop solutions, especially in critical scenarios. However, none of the existing systems for emotion recogniti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b566cb6bba591f4a98846d27054787
https://doi.org/10.1109/tcyb.2022.3185119
https://doi.org/10.1109/tcyb.2022.3185119
Autor:
Gianluca Franceschini, Mingzhou Li, Mohammed A. Osman, Xue Wang, Gustavo N Marta, Shanbo Cao, Yang Luo, Yoichi Naito, Giuseppe Lippi, Nanlin Hu, Pin Zhang, Armando Orlandi, Jian Yue, Binghe Xu, Fei Ma, Peng Yuan, Wenmiao Wang, Jiayu Wang, Anjie Zhu, Qing Li
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 875-887 (2021)
Cancer Biology & Medicine
Cancer Biology & Medicine
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eec7597e8f8455bc6bf795de0f78bc08
http://www.cancerbiomed.org/index.php/cocr/article/view/1860
http://www.cancerbiomed.org/index.php/cocr/article/view/1860
Publikováno v:
2022 IEEE International Conference on Multimedia and Expo (ICME).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18ae767eafec0568ebdeecf585800ce5
https://doi.org/10.1109/icme52920.2022.9859992
https://doi.org/10.1109/icme52920.2022.9859992